title: Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.
abstract: BACKGROUND
  Prostanoids have played an important role in the treatment of pulmonary arterial hypertension (PAH). However, whether prostanoid therapy provides a survival advantage is still not clear. The aim of this meta-analysis was to evaluate the efficacy and safety of prostanoids in PAH, focusing on the improvement in overall survival.
  
  
  METHODS
  Trials were identified from the Cochrane Library, EMBASE, and PUBMED databases. We calculated risk ratios (RR) for dichotomous data and weighted mean differences with 95 % confidence intervals (CI) for continuous data.
  
  
  RESULTS
  Fourteen trials with a total of 2,244 adult patients (1,189 patients in the prostanoid treatment group and 1,055 patients in the placebo group) were included in the meta-analysis. All-cause mortality rate in the control group was 4.17 %. In a 13.4-week follow-up, prostanoid treatment was associated with a 44 % reduction in mortality (RR 0.56; 95 % CI 0.35-0.88; P = 0.01).Subgroup analysis suggested that only treatment with intravenous prostanoids provided a survival benefit. Compared with placebo, prostanoids significantly reduced clinical worsening (RR 0.60; 95 % CI 0.46-0.80; P = 0.0003), increased the 6-min walk distance by 27.95 m, reduced mean pulmonary arterial pressure and pulmonary vascular resistance, and increased the cardiac index and mixed venous oxygen saturation. However, patients receiving prostanoid treatment showed a much higher incidence (RR 3.25; 95 % CI 2.07-5.10; P<0.00001) of withdrawal due to its adverse effects.
  
  
  CONCLUSIONS
  The results of this meta-analysis suggest that treatment with prostanoids improves the survival of patients with PAH.
authors.affiliation: State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beilishi Road, Xicheng District, Beijing, 100037, China.
authors.forename: Yaguo
authors.initials: Y
authors.lastname: Zheng
authors.forename: Tao
authors.initials: T
authors.lastname: Yang
authors.forename: Guo
authors.initials: G
authors.lastname: Chen
authors.forename: Enci
authors.initials: E
authors.lastname: Hu
authors.forename: Qing
authors.initials: Q
authors.lastname: Gu
authors.forename: Changming
authors.initials: C
authors.lastname: Xiong
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D065627:Familial Primary Pulmonary Hypertension; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011453:Prostaglandins / Q000009:adverse effects / Q000627:therapeutic use*; D016138:Walking
chemical_list: D000959:Antihypertensive Agents; D011453:Prostaglandins
references.citation: Chest. 2012 Aug;142(2):448-456
references.pmid: 22281797
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: N Engl J Med. 2004 Sep 30;351(14):1425-36
references.pmid: 15459304
references.citation: J Am Coll Cardiol. 2002 May 1;39(9):1496-502
references.pmid: 11985913
references.citation: Eur Heart J. 2009 Feb;30(4):394-403
references.pmid: 19155250
references.citation: Curr Opin Pulm Med. 2010 May;16 Suppl 1:S11-9
references.pmid: 20375660
references.citation: J Cardiovasc Pharmacol. 2003 Feb;41(2):293-9
references.pmid: 12548091
references.citation: J Am Coll Cardiol. 2003 Jun 18;41(12):2119-25
references.pmid: 12821234
references.citation: Cardiology. 2011;120(3):157-65
references.pmid: 22212696
references.citation: Eur Heart J. 2008 Nov;29(21):2592-600
references.pmid: 18664462
references.citation: Eur Respir J. 2006 Dec;28(6):1195-203
references.pmid: 16899485
references.citation: N Engl J Med. 1992 Jul 9;327(2):70-5
references.pmid: 1603138
references.citation: Circ J. 2010 Jul;74(7):1458-64
references.pmid: 20519876
references.citation: J Am Coll Cardiol. 2012 Sep 25;60(13):1192-201
references.pmid: 22995024
references.citation: Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4
references.pmid: 11897647
references.citation: N Engl J Med. 1996 Feb 1;334(5):296-301
references.pmid: 8532025
references.citation: Eur Respir J. 2006 Oct;28(4):691-4
references.pmid: 17012628
references.citation: Am Heart J. 2007 Jun;153(6):1037-47
references.pmid: 17540207
references.citation: Lancet. 1984 May 12;1(8385):1046-7
references.pmid: 6143976
references.citation: J Heart Lung Transplant. 2010 Feb;29(2):137-49
references.pmid: 20022264
references.citation: Circulation. 2013 Feb 5;127(5):624-33
references.pmid: 23307827
references.citation: Eur Heart J. 2009 Oct;30(20):2493-537
references.pmid: 19713419
references.citation: Respir Res. 2010 Jan 29;11:12
references.pmid: 20113497
references.citation: J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54
references.pmid: 19555858
references.citation: Curr Med Res Opin. 2013 Aug;29(8):889-99
references.pmid: 23647397
references.citation: Eur Respir J. 2008 Apr;31(4):891-901
references.pmid: 18378784
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Chest. 2007 Sep;132(3):757-63
references.pmid: 17400684
references.citation: Am J Respir Crit Care Med. 2006 Dec 1;174(11):1257-63
references.pmid: 16946127
references.citation: Chest. 2012 Dec;142(6):1383-1390
references.pmid: 22628490
references.citation: Circulation. 2012 Jul 17;126(3):349-56
references.pmid: 22696079
references.citation: Ann Intern Med. 1990 Apr 1;112(7):485-91
references.pmid: 2107780
references.citation: Epidemiol Rev. 1987;9:1-30
references.pmid: 3678409
references.citation: N Engl J Med. 2002 Aug 1;347(5):322-9
references.pmid: 12151469
references.citation: J Am Coll Cardiol. 2002 Aug 21;40(4):780-8
references.pmid: 12204511
references.citation: Ann Intern Med. 2000 Mar 21;132(6):425-34
references.pmid: 10733441
references.citation: J Am Coll Cardiol. 2010 May 4;55(18):1915-22
references.pmid: 20430262